[Image from Circadia]
Circadia
London
Founded: 2016
Contactless monitoring system for COVID-19 and respiratory disease
Circadia Health’s mission is to enable early detection of respiratory failure, a major cause of death. The company’s C100 System uses radar — no wires — to sense respiratory failure in patients up to 4 feet away. It’s meant to be an improvement over the manual method of measuring respiratory rate in which nursing staff visually count breaths per minute.
The FDA issued expedited clearance for Circadia’s contactless respiration rate (CResp) due to the demands created by COVID-19, the company announced Thursday.
“Our C100 uses radar to wirelessly look at your breathing pattern from up to 4 feet away,” Fares Siddiqui, co-founder and CEO of Circadia, told our DeviceTalks Weekly podcast. “From that we can pick up your respiratory rate and patterns and then apply machine learning in order to predict and prevent respiratory complications.”
For example, Siddiqui said, “breathlessness” is one of the early signs of distress in COVID-19 patients. “We can pick that up and enable timely interventions effectively.” –TS
Investors include: Village Global, SOSV, and Particular Ventures.
